GOAL.MD review

This is the most transparent microdose here and one of the worst-value ones, which is exactly why it is worth reading. GOAL.MD publishes the dose ceiling and the full week-by-week titration behind its microdose price, tells you plainly that needing more means graduating to the standard program, and does not auto-bill any compounded plan. It then charges within a couple of dollars of the unrestricted plan for roughly a fifth of the maximum dose — and more across a year, because the first-month credit that applies to the standard plans explicitly excludes the microdose. The page's own metadata advertises that excluded discount.

Vs median

$22/mo above the $175 median across the 299 of 548 programs here that publish a plain monthly rate

Market

$59–$1,300/mo is the full published spread on this site

Structure

Same price at every dose

Consult

Included in the price

Dietitian

Not confirmed

Labs

Not required

Pricing

Flat at every dose

GOAL.MD says it uses a 503B outsourcing facility, but does not say which one. No bloodwork is required before you start. A clinician review is included in the price.

GOAL.MD is a veteran-owned, physician-led telehealth practice trading under a named legal entity, with a published phone line and staffed weekday hours. It sells compounded semaglutide, compounded tirzepatide, a capped Semaglutide Micro-Dose, a combination product, brand-name GLP-1 access and a wide anti-aging catalog. Medications are prepared by licensed U.S. 503A and 503B compounding pharmacies under USP <797> sterile standards, and the Micro-Dose program specifically states 503B. Content is medically reviewed by a named physician whose NPI verifies as an active record in the CMS registry. The practice serves 48 states, offers a free consultation, and does not auto-bill its compounded programs — every order is a one-time treatment cycle you reauthorize.

The Micro-Dose costs essentially what the unrestricted program costs — $197 against $199 — while capping you at roughly a fifth of the maximum dose. And across twelve months it costs MORE, because the $50 first-month credit applies to the standard semaglutide and tirzepatide programs and explicitly excludes the Micro-Dose: $2,364 against $2,338

• The Micro-Dose page's own search listing advertises a $50-off first month that the app's footnote and pricing table both say does not apply to that product, so the search snippet promises a price the checkout does not offer
• The Micro-Dose page emits search listing carrying a price that matches none of its three real rungs — and that figure is the one a search engine reads
• The reviewing physician's NPI taxonomy is obstetrics and gynecology rather than obesity or metabolic medicine, despite the chief-physician framing on a GLP-1 weight-loss practice
• The FAQ claims coverage in 48 states but publishes no state list, so eligibility cannot be checked without contacting them
• Brand-name access does auto-renew, an exception that sits against the site's headline no-auto-billing promise
• Compounded GLP-1s are not FDA-approved, and intentional microdosing is off-label and unproven

GOAL.MD is one of 548 low-dose GLP-1 programs compared on this site, and 299 of them publish a monthly rate you can read before signing up. The full list puts every published price in one place, with the companies that pay us listed first — something we state there, on the page it applies to.

Intentional GLP-1 microdosing is off-label and unproven — no randomized trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.

• What the evidence actually shows
• Microdosing semaglutide
• Titrating up from a microdose
• What a flat price costs at a low dose
• Titration planner